A new clinical trial from the All India Institute of Medical Sciences (AIIMS) in New Delhi suggests that a structured 12-week yoga programme can do something most drugs have struggled to do — measurably shift the underlying biology of Alzheimer’s disease. Patients in the trial showed sharp drops in amyloid-beta-40, phosphorylated tau, C-reactive protein and oxidative stress markers, alongside rising levels of brain-derived neurotrophic factor (BDNF) and the protective amyloid-beta-42.
Published in late 2025 and authored by Meenakshi Kaushik, Manjari Tripathi and Rima Dada at AIIMS New Delhi, the study is one of the first to track Alzheimer’s pathology biomarkers — not just symptoms — in response to a yoga intervention. Crucially, this trial enrolled people already diagnosed with Alzheimer’s, going beyond the at-risk populations studied in earlier UCLA research.
What The AIIMS Trial Found
The investigators recruited 30 patients with Alzheimer’s disease (mean age 66.4) and 20 age-matched healthy controls (mean age 64.4) through AIIMS’s department of neurology. Participants completed a 12-week supervised yoga programme combining asanas, pranayama and meditation. Blood samples and neurocognitive testing were performed before and after the intervention.
Cognitive outcomes shifted in the right direction. Montreal Cognitive Assessment (MoCA) scores rose significantly in the Alzheimer’s group (p < 0.01), with the largest gains in language, attention and memory. Geriatric Depression Scale (GDS) scores fell, indicating mood improvement.
The biomarker panel is what makes this trial unusual. The Alzheimer’s group showed:
- Lower amyloid-beta-40 (p < 0.05) — a peptide tied to plaque formation
- Reductions in phosphorylated tau (pTau 181 and pTau 217), which mark neurodegeneration
- Lower C-reactive protein (CRP) and 8-OHdG, indicators of inflammation and oxidative DNA damage
- Reduced APOE levels
- Higher amyloid-beta-42 (p < 0.05) and improved Aβ-42/Aβ-40 ratio — a pattern associated with healthier brain clearance
- Increased BDNF (p < 0.05), a growth factor linked to neuroplasticity
BDNF is particularly interesting. Often called “fertilizer for the brain,” it supports neuron survival and synaptic plasticity, and tends to fall in Alzheimer’s disease. Watching it climb after a non-pharmacological intervention is the sort of signal neurologists want to see.
Why It Matters
Most Alzheimer’s drug development has focused on targeting amyloid plaques directly, with mixed clinical results and significant side effect profiles. The AIIMS trial points to a different strategy: a low-cost, low-risk behavioural intervention that appears to nudge multiple biological pathways at once — inflammation, oxidative stress and amyloid handling — rather than a single target.
It also extends a body of yoga-brain research that has been gathering momentum. UCLA’s team has shown that Kundalini yoga helped prevent brain shrinkage in women at risk for Alzheimer’s, and a separate UCLA trial reported that yoga outperformed memory training on cognitive endpoints. The AIIMS work moves the conversation from “at risk” populations to people with a confirmed diagnosis.
The size of the sample is modest — 30 patients — and the trial did not include an active comparator arm of, say, memory training or general exercise. So the findings need replication in larger, multi-centre studies before yoga can be prescribed alongside conventional Alzheimer’s care. But the direction of the biomarker shifts is consistent with what neuroimaging and inflammatory studies have been suggesting for years.
What The Yoga Programme Looked Like
The AIIMS protocol followed the integrated approach that has become standard in Indian clinical yoga research: gentle asanas to maintain mobility and circulation, pranayama to regulate the autonomic nervous system, and meditation to train attention. While the paper does not prescribe a single sequence, the practices broadly map onto what most home practitioners can already access.
Gentle, supported poses suitable for older adults — including chair-based variations — form the physical foundation. Slow nasal breathing techniques such as nadi shodhana (alternate nostril breathing) are typically used to downshift the stress response. Seated meditation, often only 10–15 minutes, builds the attentional capacity that MoCA testing measures.
For readers wanting to understand the breath component in more depth, our complete pranayama guide walks through the physiology and the most commonly studied techniques.
What This Means For You
You do not need to wait for a diagnosis to apply the practical lesson here. The trial reinforces a now-familiar story: a sustained, gentle practice that combines movement, breath and mental focus seems to influence brain health at the cellular level, not just the subjective level.
Three takeaways stand out for everyday practitioners:- Consistency beats intensity. The AIIMS group practised regularly across 12 weeks. There is no evidence that ramping up to harder poses is what shifted the biomarkers — it was the steady, integrated routine.
- Breath and meditation appear to do real work. The pranayama and meditation segments are the parts most often skipped in studio classes. They were not optional in this trial.
- Adaptive practice is appropriate. For older adults, falls risk is a real consideration. Our guide to yoga for seniors outlines safe progressions, and earlier research from other Alzheimer’s prevention studies has emphasised the same point.
People who already have a diagnosis, or who are caring for someone who does, should bring any change in routine to a neurologist or geriatrician first. Yoga is complementary, not a substitute for medical care.
Key Takeaways
- A 12-week AIIMS New Delhi yoga trial in 30 Alzheimer’s patients reported significant cognitive improvement and meaningful shifts in disease biomarkers.
- Amyloid-beta-40, phosphorylated tau, CRP, oxidative stress and APOE all fell; the protective Aβ-42 and BDNF rose.
- The intervention combined asana, pranayama and meditation — the classical three-pronged yoga prescription.
- Findings echo earlier UCLA research in at-risk populations but extend the signal to people with a confirmed diagnosis.
- Larger trials with active comparators and longer follow-up are needed before yoga can be formally integrated into Alzheimer’s care pathways.
Source: Kaushik M, Tripathi M, Dada R. “Yoga Modulates Alzheimer’s Disease Pathophysiology by Targeting Key Biomarkers, Oxidative Stress, Inflammation, and Neurocognition.” All India Institute of Medical Sciences, New Delhi (2025). PMC12732554.
